English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary   Objective  To determine the efficacy and safety of linagliptin in initial combination with metformin in patients with type 2 diabetes.    Methods  This 1‐year randomised, double‐blind study was an extension of a 6‐month randomised controlled trial, in which adults with type 2 diabetes received one of six treatment regimens (linagliptin 2.5 mg plus metformin 500 mg bid, linagliptin 2.5 mg plus metformin mg 1000 bid, metformin 1000 mg bid, metformin 500 mg bid, linagliptin 5 mg qd or placebo). In the extension, patients in the first three treatment groups continued their regimen (non‐switched group,  n  =   333) while the metformin 500 mg bid, linagliptin 5 mg qd and placebo groups were re‐randomised to one of the three continuing regimens (switched group,  n  =   233).    Results  All three non‐switched groups maintained reductions in glycosylated haemoglobin (HbA1c; mean ± standard deviation reductions across the 1.5‐year period: linagliptin 2.5 plus metformin 1000 bid, –1.63 ± 1.05%; linagliptin 2.5 plus metformin 500 bid, –1.32 ± 1.06%; metformin 1000 bid, –1.25 ± 0.91%) while the switched groups showed additional HbA1c reductions. During the extension, there were no clinically meaningful changes in body weight in any group. Adverse event rates were similar between groups, with most events being mild or moderate, and the incidence of investigator‐defined hypoglycaemia was low, with no severe events.    Discussion  Initial combination of linagliptin and metformin was well tolerated over the 1‐year extension period, with low risk of hypoglycaemia, and improved glycaemic control vs. metformin alone.    Conclusion  The initial combination of linagliptin and metformin appears to provide a useful treatment option in patients whose blood glucose levels are increased to an extent that metformin monotherapy may not achieve treatment targets.

international journal of clinical practice

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double‐blind 1‐year extension study